Matthew J. Maurer, DMSc
@maurerstats
Associate Professor of Biostatistics & Medicine at Mayo Clinic, #lymphoma researcher #lymsm. Husband; dad of 3. Tweets mine. He/him.
ID: 2233351410
https://www.mayo.edu/research/labs/lymphoma-biostatistics-data-science/overview 06-12-2013 18:17:25
4,4K Tweet
2,2K Takipçi
926 Takip Edilen
Are you all caught up on your HemOnc Pulse episodes? If not, this is the perfect weekend to check out the recent episodes, ft. hem-oncs like Jay Spiegel, Aditi Shastri, MD, Matthew J. Maurer, DMSc, Alan Skarbnik, and of course our host chadi nabhan MD, MBA, FACP. 🎧 buff.ly/3H0FATv
AMAZING. Andrew M. Evens, DO, MBA, MSc Matthew J. Maurer, DMSc & Dr. Parsons collected data on THOUSANDS of Hodgkin PTs from all over the WORLD to answer questions we couldn’t answer B4. The full story on #HealthcareUnfiltered. Checkout: hodgkinconsortium.com Link: podcasts.apple.com/us/podcast/hea…
Excited to report our new paper on FL, great work by Jordan Krull #lymsm Follicular lymphoma B cells exhibit heterogeneous transcriptional states with associated somatic alterations and tumor microenvironments: Cell Reports Medicine cell.com/cell-reports-m…
Monumental effort by GLOW team in publishing the largest analysis of NLPHL to date and answering many key questions about age specific risks, the prognostic impact of variant patterns, and developing a new LP-IPS: ascopubs.org/doi/10.1200/JC… GLOW: Global nLPHL One Working Group Journal of Clinical Oncology Jamie Flerlage
A huge congratulations to Drs. Michael Sargent Binkley & Jamie Flerlage and the entire GLOW: Global nLPHL One Working Group team on publication of an NLPHL-specific prognostic score (LP-IPS) in Journal of Clinical Oncology. Deeply grateful to have participated in this high-impact study! #lymsm #NLPHLsm ascopubs.org/doi/pdf/10.120…
International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma: important work by my Wilmot Cancer Institute colleague Jamie Flerlage Journal of Clinical Oncology ascopubs.org/doi/full/10.12…
What clinicians should know about surrogate endpoints Nice work Côme Bommier Matthew J. Maurer, DMSc Many great examples woven into a thoughtful piece ashpublications.org/blood/article/… Blood Journal
The FDA ODAC voted in favor of the use of MRD-negativity as an endpoint for accelerated approval in #myeloma trials. Read more about the vote, with remarks from Chris Hourigan (Fralin Biomedical Research Institute), Ravi A Madan M.D. (National Cancer Institute), & Matthew J. Maurer, DMSc (Mayo Clinic). 📖 buff.ly/4aF8oxb
FINALLY OUT ! "What clinicians should know about surrogate end points in hematologic malignancies" A clinician-friendly review building a bridge between clinicians and surrogacy specialists. Written along with Matthew J. Maurer, DMSc and Jérôme Lambert. ashpublications.org/blood/article/…
Great week at ASH Clinical Research Training Institute. Congrats to our rising stars - the future is bright! ⭐️🌟⭐️ Follow: Seda Tolu Laura Samples, MD Zulfa Omer Yun Kyoung Ryu #ASHCRTI
Check out our latest paper in Journal of Clinical Oncology on surrogacy of endpoints in 1L #CLL trials! Led by Florian Simon, we systematically studied the association of PFS and MRD with OS. Some findings in a brief 🧵 👇 ascopubs.org/doi/10.1200/JC…